These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


256 related items for PubMed ID: 7781143

  • 1. Pretreatment H2 receptor antagonists that differ in P450 modulation activity: comparative effects on paclitaxel clearance rates and neutropenia.
    Slichenmyer WJ, Donehower RC, Chen TL, Bowling MK, McGuire WP, Rowinsky EK.
    Cancer Chemother Pharmacol; 1995; 36(3):227-32. PubMed ID: 7781143
    [Abstract] [Full Text] [Related]

  • 2. Effects of three H2-receptor antagonists (cimetidine, famotidine, ranitidine) on serum gastrin level.
    Ohsawa T, Hirata W, Higichi S.
    Int J Clin Pharmacol Res; 2002; 22(2):29-35. PubMed ID: 12503773
    [Abstract] [Full Text] [Related]

  • 3. Comparative study of the speed of acid-suppressing effects of oral administration of cimetidine and famotidine.
    Adachi K, Komazawa Y, Mihara T, Azumi T, Fujisawa T, Katsube T, Furuta K, Kinoshita Y.
    J Gastroenterol Hepatol; 2005 Jul; 20(7):1012-5. PubMed ID: 15955208
    [Abstract] [Full Text] [Related]

  • 4. Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin.
    Rowinsky EK, Jiroutek M, Bonomi P, Johnson D, Baker SD.
    Clin Cancer Res; 1999 Apr; 5(4):767-74. PubMed ID: 10213211
    [Abstract] [Full Text] [Related]

  • 5. Clinical evaluation of the effect of omeprazole, cimetidine, famotidine and ranitidine on histamine induced cutaneous wheal and flare response.
    Saha N, Sachdev A, Bhasin DK, Sankaranahyanan A, Khosla PP, Singh K, Sharma PL.
    Int J Clin Pharmacol Ther Toxicol; 1993 Jul; 31(7):322-5. PubMed ID: 8103763
    [Abstract] [Full Text] [Related]

  • 6. A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors.
    Diab SG, Baker SD, Joshi A, Burris HA, Cobb PW, Villalona-Calero MA, Eckhardt SG, Weiss GR, Rodriguez GI, Drengler R, Kraynak M, Hammond L, Finizio M, Von Hoff DD, Rowinsky EK.
    Clin Cancer Res; 1999 Feb; 5(2):299-308. PubMed ID: 10037178
    [Abstract] [Full Text] [Related]

  • 7. Phase I and pharmacological study of single paclitaxel administered weekly for heavily pre-treated patients with epithelial ovarian cancer.
    Takano M, Kikuchi Y, Kita T, Suzuki M, Ohwada M, Yamamoto T, Yamamoto K, Inoue H, Shimizu K.
    Anticancer Res; 2002 Feb; 22(3):1833-8. PubMed ID: 12168878
    [Abstract] [Full Text] [Related]

  • 8. Salvage weekly paclitaxel in recurrent ovarian cancer.
    Abu-Rustum NR, Aghajanian C, Barakat RR, Fennelly D, Shapiro F, Spriggs D.
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
    [Abstract] [Full Text] [Related]

  • 9. Effect of oral H2-receptor antagonists on left ventricular systolic function and exercise capacity in patients with chronic stable heart failure.
    Lucas BD, Williams MA, Mohiuddin SM, LaMadrid LJ, Schroeder LJ, Hilleman DE.
    Pharmacotherapy; 1998 Oct; 18(4):824-30. PubMed ID: 9692655
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Phase I and pharmacologic study of a 3-hour infusion of paclitaxel followed by cisplatinum and 5-fluorouracil in patients with advanced solid tumors.
    Bhalla KN, Kumar GN, Walle UK, Ibrado AM, Javed T, Stuart RK, Reed C, Arbuck SG, Walle T.
    Clin Cancer Res; 1999 Jul; 5(7):1723-30. PubMed ID: 10430075
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [A phase II clinical study of China-made paclitaxel in the treatment of cancer patients].
    Wu H, Guan Z, Lin T.
    Zhonghua Zhong Liu Za Zhi; 1998 Mar; 20(2):148-52. PubMed ID: 10920970
    [Abstract] [Full Text] [Related]

  • 15. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
    Polyzos A, Kosmas C, Tsavaris N, Toufexi H, Lagadas A, Gogas H, Giannakopoulos K, Kouraklis G, Griniatsos J, Felekouras E, Tsigris C, Nikiteas N, Papadopoulos O, Giannopoulos A.
    Anticancer Res; 2007 Mar; 27(3B):1645-51. PubMed ID: 17595790
    [Abstract] [Full Text] [Related]

  • 16. Comparison of famotidine with cimetidine and ranitidine.
    Berardi RR, Tankanow RM, Nostrant TT.
    Clin Pharm; 1988 Apr; 7(4):271-84. PubMed ID: 2896559
    [Abstract] [Full Text] [Related]

  • 17. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.
    Tung N, Berkowitz R, Matulonis U, Quartulli M, Seiden M, Kim Y, Niloff J, Cannistra SA.
    Gynecol Oncol; 2000 May; 77(2):271-7. PubMed ID: 10785477
    [Abstract] [Full Text] [Related]

  • 18. Effect of pre-operative short course famotidine on tumor infiltrating lymphocytes in colorectal cancer: a double blind, placebo controlled, prospective randomized study.
    Kapoor S, Pal S, Sahni P, Dattagupta S, Kanti Chattopadhyay T.
    J Surg Res; 2005 Dec; 129(2):172-5. PubMed ID: 15882879
    [Abstract] [Full Text] [Related]

  • 19. Hepatoprotective, antinociceptive and antioxidant activities of cimetidine, ranitidine and famotidine as histamine H2 receptor antagonists.
    Ahmadi A, Ebrahimzadeh MA, Ahmad-Ashrafi S, Karami M, Mahdavi MR, Saravi SS.
    Fundam Clin Pharmacol; 2011 Feb; 25(1):72-9. PubMed ID: 20070855
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 13.